The fight against Alzheimer’s disease has received a significant boost with the unveiling of precisely how lecanemab, marketed as Leqembi, works to slow cognitive decline. For years, this monoclonal antibody therapy has shown promise in clearing the toxic amyloid plaques associated with the disease, but the underlying mechanism remained elusive. Now, researchers at VIB and KU Leuven have pinpointed the critical role of the antibody’s ‘Fc fragment’ in activating the brain’s immune cells, known as microglia, to effectively remove these damaging deposits. This breakthrough, published in Nature Neuroscience, offers a clearer path toward developing even more targeted and effective Alzheimer’s treatments.
Alzheimer’s disease, a devastating neurodegenerative condition, affects tens of millions worldwide. The hallmark of the disease is the accumulation of amyloid plaques – abnormal clusters of proteins – in the brain. These plaques disrupt communication between neurons, ultimately leading to cognitive impairment and dementia. While the brain’s immune system, specifically microglia, naturally attempts to clear these plaques, their efforts are often insufficient. Lecanemab, approved by the U.S. Food and Drug Administration (FDA) in January 2023 according to the FDA, aims to bolster this natural clearance process, but understanding how it did so was a crucial missing piece of the puzzle.
Unlocking the Mechanism: The Role of the Fc Fragment
Antibodies, like lecanemab, are complex proteins with two primary components. One part binds directly to the target – in this case, amyloid plaques – while the other, the Fc fragment, acts as a signal to the immune system. Previous research hinted at microglia’s involvement in plaque removal, but a direct link to lecanemab’s effectiveness, and the specific role of the Fc fragment, hadn’t been definitively established. The team led by Professor Bart De Strooper at VIB-KU Leuven has now provided that crucial evidence.
“Our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer’s disease,” explains Dr. Giulia Albertini, co-first author of the study. “We show that the therapy’s efficacy relies on the antibody’s Fc fragment, which activates microglia to effectively clear amyloid plaques.” The Fc fragment, she elaborates, functions like an “anchor,” allowing microglia to latch onto plaques and become “reprogrammed” to clear them more efficiently. This discovery resolves long-standing uncertainties in the field and provides a blueprint for future therapeutic development.
To conduct their research, the team utilized a specialized Alzheimer’s mouse model engineered to include human microglial cells. This allowed them to observe, with unprecedented detail, how lecanemab interacts with human immune cells and promotes plaque clearance. Crucially, when the Fc fragment was removed, the antibody lost its ability to stimulate plaque removal, confirming its essential role. Magdalena Zielonka, also a co-first author, emphasized the strength of this approach: “The fact that we used human microglia within a controlled experimental model was a major strength of our study. This allowed us to test the highly antibodies used in patients and observe human-specific responses with unprecedented resolution.”
Inside the Brain’s Cleanup Process: Phagocytosis and Lysosomal Activity
The researchers didn’t stop at identifying the Fc fragment’s importance. they also delved into the cellular processes activated by its engagement with microglia. They discovered that the activation of microglia triggered key processes involved in plaque removal, including phagocytosis – the engulfing of cellular debris – and lysosomal activity – the breakdown of waste materials within cells. These processes were only observed when the Fc fragment was present and functional, highlighting its critical role in initiating the brain’s cleanup mechanism.
Further investigation using advanced techniques like single-cell and spatial transcriptomics revealed a specific gene activity pattern in microglia associated with effective plaque removal. This pattern involved strong expression of the gene SPP1, identified using NOVA-ST, a method developed by the Stein Aerts lab (VIB-KU Leuven). This discovery provides a deeper understanding of the molecular changes occurring within microglia during plaque clearance and could potentially be used to identify biomarkers for treatment response.
Implications for Future Alzheimer’s Therapies
The findings from VIB and KU Leuven have significant implications for the future of Alzheimer’s disease treatment. By precisely defining the microglial program responsible for clearing plaques, the research opens doors to novel therapeutic strategies. Instead of relying solely on antibodies to activate microglia, future therapies may be able to directly stimulate these immune cells, potentially leading to more effective and safer treatments.
“This opens doors to future therapies that may activate microglia without requiring antibodies,” concludes Professor De Strooper. “Understanding the importance of the Fc fragment helps guide the design of next-generation Alzheimer’s drugs.” This approach could potentially circumvent some of the side effects associated with current antibody therapies, such as amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding. The Alzheimer’s Association provides detailed information on ARIA and lecanemab’s safety profile.
The Challenge of Alzheimer’s Disease: A Global Health Crisis
Alzheimer’s disease represents a growing global health crisis. According to the World Health Organization (WHO), more than 55 million people worldwide are living with dementia, with Alzheimer’s disease being the most common form. The WHO estimates that nearly 10 million new cases of dementia are diagnosed each year. This number is projected to rise dramatically as the global population ages, placing an immense strain on healthcare systems and families.
The economic burden of Alzheimer’s disease is also substantial. In the United States alone, the Alzheimer’s Association estimates that the total cost of care for individuals with Alzheimer’s and other dementias will reach $345 billion in 2023. This figure includes healthcare costs, as well as lost productivity and unpaid caregiving. Developing effective treatments and preventative strategies is therefore not only a medical imperative but also an economic necessity.
While lecanemab represents a significant step forward, It’s not a cure. The drug has been shown to slow the rate of cognitive decline, but it does not halt the progression of the disease entirely. The treatment is not suitable for all patients, and careful monitoring is required to manage potential side effects. Ongoing research is crucial to develop more effective and personalized therapies for Alzheimer’s disease.
The research conducted at the VIB-KU Leuven Center for Brain & Disease Research was supported by the European Research Council (ERC), Alzheimer’s Association USA, Research Foundation Flanders (FWO), Queen Elisabeth Medical Foundation for Neurosciences, Stichting Alzheimer Onderzoek — Fondation Recherche Alzheimer (STOPALZHEIMER.BE), KU Leuven, VIB, and UK Dementia Research Institute University College London.
The next key milestone in Alzheimer’s research will be the continued monitoring of patients receiving lecanemab, as well as the ongoing development of new therapies targeting different aspects of the disease. Researchers are also exploring potential preventative strategies, such as lifestyle modifications and early detection methods. The hope is that, through continued research and innovation, People can ultimately conquer this devastating disease.
Have you or a loved one been affected by Alzheimer’s disease? Share your thoughts and experiences in the comments below. Please also share this article with your network to raise awareness about this important research.
Worth a look